We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in Bio-Rad (BIO) Right Now
Read MoreHide Full Article
Bio-Rad Laboratories, Inc. (BIO - Free Report) has been on a healthy growth trajectory of late. Positive tidings on the regulatory front have lent the company a competitive edge in the MedTech space. With solid prospects, this Zacks Rank #1 (Strong Buy) stock is an attractive pick at the moment.
Bio-Rad has outperformed its industry over the past six months. The stock has gained 21.4%, higher than the S&P 500’s 9.8% and the industry’s 5.9%.
The stock has a market cap of $7.92 billion. The company’s next five-year earnings growth rate is also favorable at 29.7% compared with the 18.8% rise of its industry and 11.9% gain of the S&P 500.
The company has a positive earnings surprise of 59.2% for the last four quarters. Also, it has a long-term expected earnings growth rate of 20%.
The company’s estimate revision trend for the current year has been positive. In the past couple of months, three estimates moved north, with no movement in the opposite direction. Earnings estimates rose around 18.4% to $5.86 per share.
Let’s find out whether the recent positive trend is a sustainable one.
3 Factors Boosting Bio-Rad
Strong Q4 Results: The market is upbeat about Bio-Rad’s strong quarterly performance with earnings and sales showing a sharp year-over-year improvement in the fourth quarter. Sales growth was majorly driven by the company’s Life Science product lines. Within Diagnostics, instrument placement was solid throughout 2017.
Guidance Solid: A promising 2018 guidance further instills confidence in the stock. For 2018, Bio-Rad expects currency neutral revenue growth of approximately 3.5-4%. This outlook takes continued strong sales in Life Science segment and increased growth for Diagnostics into account.
Positive Tidings in Regulatory Front:Recently, Bio-Rad announced the receipt of 510(k) FDA clearance for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad’s IH-System Gel Reagents for manual blood typing methods.
All these factors are boosting investor confidence in the stock.
athenahealth has a projected long-term growth rate of 20.7%. The stock provided a positive earnings surprise of 73.4% in the last quarter.
MEDNAX has an expected long-term growth rate of 10%. The stock provided a positive earnings surprise of 3.6% in the last quarter.
ICU Medical has an expected long-term growth rate of 10%. The stock provided a positive earnings surprise of 204.1% in the last quarter.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Here's Why You Should Invest in Bio-Rad (BIO) Right Now
Bio-Rad Laboratories, Inc. (BIO - Free Report) has been on a healthy growth trajectory of late. Positive tidings on the regulatory front have lent the company a competitive edge in the MedTech space. With solid prospects, this Zacks Rank #1 (Strong Buy) stock is an attractive pick at the moment.
Bio-Rad has outperformed its industry over the past six months. The stock has gained 21.4%, higher than the S&P 500’s 9.8% and the industry’s 5.9%.
The stock has a market cap of $7.92 billion. The company’s next five-year earnings growth rate is also favorable at 29.7% compared with the 18.8% rise of its industry and 11.9% gain of the S&P 500.
The company has a positive earnings surprise of 59.2% for the last four quarters. Also, it has a long-term expected earnings growth rate of 20%.
The company’s estimate revision trend for the current year has been positive. In the past couple of months, three estimates moved north, with no movement in the opposite direction. Earnings estimates rose around 18.4% to $5.86 per share.
Let’s find out whether the recent positive trend is a sustainable one.
3 Factors Boosting Bio-Rad
Strong Q4 Results: The market is upbeat about Bio-Rad’s strong quarterly performance with earnings and sales showing a sharp year-over-year improvement in the fourth quarter. Sales growth was majorly driven by the company’s Life Science product lines. Within Diagnostics, instrument placement was solid throughout 2017.
Guidance Solid: A promising 2018 guidance further instills confidence in the stock. For 2018, Bio-Rad expects currency neutral revenue growth of approximately 3.5-4%. This outlook takes continued strong sales in Life Science segment and increased growth for Diagnostics into account.
Positive Tidings in Regulatory Front:Recently, Bio-Rad announced the receipt of 510(k) FDA clearance for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad’s IH-System Gel Reagents for manual blood typing methods.
All these factors are boosting investor confidence in the stock.
Other Key Picks
Other top-ranked stocksin the broader medical sector are MEDNAX, Inc. (MD - Free Report) , ICU Medical, Inc. (ICUI - Free Report) and athenahealth, Inc. . All the stocks sport a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
athenahealth has a projected long-term growth rate of 20.7%. The stock provided a positive earnings surprise of 73.4% in the last quarter.
MEDNAX has an expected long-term growth rate of 10%. The stock provided a positive earnings surprise of 3.6% in the last quarter.
ICU Medical has an expected long-term growth rate of 10%. The stock provided a positive earnings surprise of 204.1% in the last quarter.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>